Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Neoplasms 1Liver Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 184Carboplatin 132Paclitaxel 101Cisplatin 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × Cell- and Tissue-Based Therapy × Clear all
NCT06084884 2026-05-22

ATHENA

AstraZeneca

Phase 1/2 Active not recruiting
94 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02193503 2023-09-28

MVX-ONCO-1 in Patients With Solid Tumor

Maxivax SA

Phase 1 Active not recruiting
34 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡